6 assets in Distal Biliary Tract Carcinoma

Therapeutic assets addressing Distal Biliary Tract Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Distal Biliary Tract Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cobimetinib Distal Biliary Tract Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pantoprazole Distal Biliary Tract Carcinoma	Washington University School of Medicine	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Distal Biliary Tract Carcinoma	National Cancer Institute (NCI)	P2	CC (44)
Cis-Diamminedichloroplatinum Ii Distal Biliary Tract Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Elimusertib Distal Biliary Tract Carcinoma	National Cancer Institute (NCI)	P1	CC (43)